This supplement was supported by AstraZeneca.
ONCOLOGY Vol 40, Issue 8
This supplement was supported by AstraZeneca.
Advertisement
Advertisement
Trending on CancerNetwork
1
Isatuximab-Based Therapy Shows “Impressive” PFS Projections in NDMM
2
CELMoD-Based Maintenance Deepens Responses After ASCT in Multiple Myeloma
3
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
4
Subcutaneous Isatuximab Enhances Patient Experience in Multiple Myeloma
5